China Universal Asset Management Co. Ltd. Purchases 32,575 Shares of Gilead Sciences, Inc. $GILD

China Universal Asset Management Co. Ltd. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 194,103 shares of the biopharmaceutical company’s stock after purchasing an additional 32,575 shares during the quarter. Gilead Sciences makes up 1.5% of China Universal Asset Management Co. Ltd.’s holdings, making the stock its 13th largest position. China Universal Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $29,364,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Childress Capital Advisors LLC boosted its stake in shares of Gilead Sciences by 2.0% during the 3rd quarter. Childress Capital Advisors LLC now owns 14,155 shares of the biopharmaceutical company’s stock worth $2,110,000 after acquiring an additional 281 shares during the period. D.A. Davidson & CO. increased its holdings in shares of Gilead Sciences by 0.7% during the 3rd quarter. D.A. Davidson & CO. now owns 72,938 shares of the biopharmaceutical company’s stock worth $10,871,000 after acquiring an additional 519 shares during the last quarter. BOKF NA raised its stake in Gilead Sciences by 18.6% in the 3rd quarter. BOKF NA now owns 161,849 shares of the biopharmaceutical company’s stock valued at $24,124,000 after acquiring an additional 25,388 shares during the period. North Dakota State Investment Board raised its stake in Gilead Sciences by 2.7% in the 3rd quarter. North Dakota State Investment Board now owns 38,050 shares of the biopharmaceutical company’s stock valued at $5,671,000 after acquiring an additional 1,018 shares during the period. Finally, Laurel Wealth Advisors LLC bought a new stake in Gilead Sciences in the 3rd quarter valued at $29,000. 83.67% of the stock is owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly results exceeded expectations. Gilead reported adjusted EPS of $2.55, ahead of the $2.17-$2.19 analyst consensus, while revenue rose 6.8% year over year to $8.3 billion versus expectations of approximately $7.8 billion. Gilead Sciences Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Gilead raised its full-year sales forecast. The company now expects 2026 product sales of $31.0 billion to $31.3 billion, up from its previous range of $30.1 billion to $30.4 billion. The improved outlook reflects strength in HIV medicines and helped support the bullish reaction. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: HIV and oncology products drove growth. Biktarvy continued to power the HIV franchise, while cancer drug Trodelvy also contributed to sales growth, giving investors evidence that Gilead’s commercial portfolio is performing better than anticipated.
• Positive Sentiment: Lyvdelzi gained Canadian reimbursement support. A reimbursement agreement with Canada’s pan-Canadian Pharmaceutical Alliance could improve access to Gilead’s liver-disease treatment, though its near-term financial impact is likely limited. Gilead Successfully Completes Negotiations for LYVDELZI
• Neutral Sentiment: Analyst sentiment remains cautious. Robert W. Baird maintained a Hold rating, suggesting the strong results may already be reflected in the stock’s valuation and that investors want clearer evidence of sustainable growth beyond the HIV franchise. Gilead Gets a Hold from Robert W. Baird
• Negative Sentiment: Future pricing pressure is a major risk. Gilead said Medicare negotiations will reduce Biktarvy’s price by 38% beginning in 2028, creating a significant longer-term threat to revenue and margins for one of its most important products. Gilead Hikes 2026 Sales Outlook
• Negative Sentiment: The company widened its 2026 non-GAAP loss forecast. Despite the quarterly beat, the updated loss outlook highlights ongoing expenses and execution risks, tempering the otherwise strong earnings report. Gilead Widens 2026 Non-GAAP Loss Forecast

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 over the last ninety days. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 4.0%

Shares of NASDAQ:GILD opened at $165.61 on Friday. The company’s 50 day moving average price is $150.33 and its two-hundred day moving average price is $139.55. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $165.70. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period last year, the firm earned $2.47 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Morgan Stanley cut their price target on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Jefferies Financial Group reissued a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a research report on Friday, October 23rd. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $159.81.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.